Keros Therapeutics, Inc. KROS
Set alert
11.04 USD -0.32 -2.82%
At close · Oct 30
11.04 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
10.98 Day range 11.49
9.91 52-week range 21.84
- YTD
- -45.78%
- 1 year
- -26.55%
- Open
- 11.36
- Prev close
- 11.36
- Mkt cap
- 218.89M
- Vol
- 120.16K
- Avg vol
- 189.16K
- EPS
- -3.22
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.98
- High
- 11.49
- Forward P/E
- -3.00
- Beta
- 1.24
- Short ratio
- 5.28
- Inst. own
- 100.86%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 55.00
- 200-d avg
- 53.85
- 1y target
- 43.55
2Y chart
Events in this range
- Nov 6, 2024Earnings: -1.41; estimate -1.26; surprise -11.9%
- Dec 12, 2024Downgrade: William Blair · Outperform → Market Perform
- Dec 13, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Dec 13, 2024Rating: Scotiabank · Sector Outperform → Sector Outperform
- Dec 16, 2024Downgrade: Guggenheim · Buy → Neutral
- Dec 16, 2024Rating: Oppenheimer · Outperform → Outperform
- Dec 23, 2024Rating: Truist Securities · Buy → Buy
Signals (83)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 1 day ago |
| MACD: Sell Signal | Oct 30, 2026 | 1 day ago |
| MACD: Buy Signal | Oct 27, 2026 | 4 days ago |
| SMA: Bullish | Oct 22, 2026 | 1 week ago |
| SMA: Bearish | Oct 21, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 14, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 13, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 9, 2026 | 3 weeks ago |
| MACD: Sell Signal | Sep 29, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 16, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Aug 14, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Jul 16, 2026 | 3 months ago |
| SMA: Bullish | Jul 15, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 15, 2026 | 3 months ago |
| SMA: Bearish | Jul 14, 2026 | 3 months ago |
| SMA: Bullish | Jul 2, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 17, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| SMA: Bearish | May 29, 2026 | 5 months ago |
| SMA: Bullish | May 28, 2026 | 5 months ago |
| MACD: Buy Signal | May 26, 2026 | 5 months ago |
| MACD: Sell Signal | May 15, 2026 | 5 months ago |
| SMA: Bearish | May 14, 2026 | 5 months ago |
| SMA: Bullish | May 8, 2026 | 5 months ago |
| SMA: Bearish | May 7, 2026 | 5 months ago |
| SMA: Bullish | May 6, 2026 | 5 months ago |
| RSI: Oversold | Mar 27, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 19, 2026 | 7 months ago |
| SMA: Bearish | Feb 23, 2026 | 8 months ago |
| RSI: Oversold | Feb 23, 2026 | 8 months ago |
| RSI: Oversold | Feb 18, 2026 | 8 months ago |
| SMA: Bearish | Jan 26, 2026 | 9 months ago |
| SMA: Bullish | Jan 22, 2026 | 9 months ago |
| SMA: Bearish | Jan 16, 2026 | 9 months ago |
| SMA: Bullish | Jan 7, 2026 | 9 months ago |
| SMA: Bearish | Jan 5, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 18, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 4, 2025 | 11 months ago |
| RSI: Overbought | Dec 4, 2025 | 11 months ago |
| MACD: Sell Signal | Dec 1, 2025 | 11 months ago |
| RSI: Overbought | Nov 18, 2025 | 11 months ago |
| RSI: Overbought | Nov 12, 2025 | 11 months ago |
| SMA: Bullish | Nov 4, 2025 | 12 months ago |
| MACD: Buy Signal | Oct 30, 2025 | 1 year ago |
| SMA: Bearish | Oct 23, 2025 | 1 year ago |
| SMA: Bullish | Oct 21, 2025 | 1 year ago |
| SMA: Bearish | Oct 14, 2025 | 1 year ago |
| SMA: Bullish | Sep 22, 2025 | 1 year ago |
| SMA: Bearish | Sep 19, 2025 | 1 year ago |
| SMA: Bullish | Sep 18, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 15, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 15, 2025 | 1 year ago |
| SMA: Bullish | Aug 14, 2025 | 1 year ago |
| SMA: Bearish | Aug 7, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 7, 2025 | 1 year ago |
| SMA: Bullish | Jul 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 23, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 22, 2025 | 1 year ago |
| SMA: Bearish | Jul 18, 2025 | 1 year ago |
| SMA: Bullish | Jul 9, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 8, 2025 | 1 year ago |
| SMA: Bearish | Jun 13, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 9, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 3, 2025 | 1 year ago |
| MACD: Sell Signal | May 6, 2025 | 1 year ago |
| RSI: Overbought | May 1, 2025 | 1 year ago |
| RSI: Overbought | Apr 29, 2025 | 1 year ago |
| RSI: Overbought | Apr 23, 2025 | 1 year ago |
| RSI: Overbought | Apr 17, 2025 | 1 year ago |
| SMA: Bullish | Apr 10, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 10, 2025 | 1 year ago |
| RSI: Oversold | Apr 1, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 31, 2025 | 1 year ago |
| SMA: Bearish | Mar 26, 2025 | 1 year ago |
| SMA: Bullish | Mar 24, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 6, 2025 | 1 year ago |
| RSI: Oversold | Dec 12, 2024 | 1 year ago |
Key statistics
- Market cap
- 693.49M
- Enterprise value
- 178.44M
- Trailing P/E
- 0.00
- Forward P/E
- -3.00
- PEG ratio
- 0.00
- Price / sales
- 1065.26
- Price / book
- 1.26
- EPS (TTM)
- -5.22
- Beta
- 1.24
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 651.00K
- Revenue growth
- 4750.00%
- Free cash flow
- -89.32M
- Total cash
- 530.68M
- Total debt
- 19.29M
- Return on equity
- -43.82%
- Shares outstanding
- 40.51M
- Short % of float
- 7.39%
- 50-day average
- 55.00
- 200-day average
- 53.85
Analyst view
Consensus: buy
Buy
Price target (mean) 43.55 +294.4% upside
Now 11.04
- Target (low)
- 23.00
- Target (mean)
- 43.55
- Target (high)
- 76.00
Ratings (0m) 14 11 buy · 3 hold · 0 sell
- Strong buy3
- Buy8
- Hold3
- Sell0
- Strong sell0
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.51.
Financials — quick view
KROS Revenue — quarterly 0
KROS Net income — quarterly -28.71M
KROS EPS — quarterly -1.45
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -1.26 | -1.41 | -0.15 | -11.90% |
| Aug 7, 2024 | Jun 1, 2024 | -1.23 | -1.25 | -0.02 | -1.63% |
| Aug 7, 2024 | Jun 1, 2024 | -1.23 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -1.31 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -1.31 | -1.21 | +0.10 | +7.63% |
| Feb 28, 2024 | Dec 1, 2023 | -1.38 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | Truist Securities | main | Buy | Buy |
| Dec 16, 2024 | Oppenheimer | main | Outperform | Outperform |
| Dec 16, 2024 | Guggenheim | down | Buy | Neutral |
| Dec 13, 2024 | Scotiabank | main | Sector Outperform | Sector Outperform |
| Dec 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 12, 2024 | William Blair | down | Outperform | Market Perform |
About Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kerostx.com
News
- Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trial
- Keros Therapeutics Doses First Patient In Phase 2 Clinical Study Of Rinvatercept In Patients With Duchenne Muscular Dystrophy
- Keros Therapeutics Reveals $5M Share Repurchase Authorization
- Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $18
- Keros Therapeutics Q2 EPS $(1.45) Misses $(1.34) Estimate
- Keros Therapeutics To Receive $20M Milestone Payment From Takeda Under Elritercept Licensing Terms After Dosing First Patient In The ELRiSE MDS Trial
- Keros Therapeutics Q1 EPS $(1.21) Misses $(1.02) Estimate, Sales $367.000K Miss $583.333K Estimate
- Keros Therapeutics Presents Additional Data From Its Phase 1 Clinical Study Of Rinvatercept In Health Volunteers At 2026 Muscular Dystrophy Association Clinical & Scientific Conference
- Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $20
- CORRECTION: Keros Therapeutics Q4 EPS $(0.86) Misses $(0.60) Estimate, Sales $385.000K Miss $2.757M Estimate
Your note
Sign in to keep a note on KROS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GORDON CARL L | Director | Sale | Aug 12, 2024 | 0 |
| ORBIMED ADVISORS, L.L.C. | Unknown | Sale | Aug 12, 2024 | 0 |
| REGNANTE KEITH C | Chief Financial Officer | Conversion of Exercise of derivative security | Nov 2, 2023 | 0 |
| SEEHRA JASBIR | Chief Executive Officer | Conversion of Exercise of derivative security | Apr 6, 2023 | 252,856 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 12.09% | 4,899,134 | 83.87M | Sep 29, 2024 |
| Blackrock Inc. | 6.50% | 2,632,608 | 45.07M | Sep 29, 2024 |
| Alkeon Capital Management LLC | 4.68% | 1,897,601 | 32.49M | Sep 29, 2024 |
| Vanguard Group Inc | 4.58% | 1,856,418 | 31.78M | Sep 29, 2024 |
| Darwin Global Management, Ltd. | 3.76% | 1,523,732 | 26.09M | Sep 29, 2024 |
| Price (T.Rowe) Associates Inc | 3.74% | 1,514,505 | 25.93M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.37% | 961,347 | 16.46M | Sep 29, 2024 |
| ACAP Strategic Fund | 2.31% | 933,991 | 15.99M | Sep 29, 2024 |
| Price (T.Rowe) New Horizons Fund | 2.17% | 877,880 | 15.03M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.87% | 756,550 | 12.95M | Oct 30, 2024 |
| Fidelity Select Portfolios - Biotechnology | 1.63% | 661,229 | 11.32M | Oct 30, 2024 |
| Fidelity Select Portfolios - Health Care | 1.60% | 650,000 | 11.13M | Oct 30, 2024 |